Swiss-based SkyCell has successfully closed its $116 million Series D funding round, securing $59 million from Tybourne Capital Management and CC Industries. This follows a $57 million equity investment from Catalyst, M&G Investments’ purpose-led private assets strategy. The funds are earmarked for expanding SkyCell’s global footprint, with a particular focus on growth in the U.S. and Asia.
SkyCell specialises in protecting the pharmaceutical supply chain through a comprehensive approach that combines IP-protected temperature-controlled containers, software, and big data analytics. Each month, SkyCell’s containers safeguard more than $2.5 billion worth of pharmaceutical goods, including vaccines, cancer treatments, diabetes care, and diagnostic solutions.
The core of SkyCell’s cold chain technology is its proprietary software platform, SkyMind, which enhances shipment and asset management through automation and real-time visibility. SkyMind enables pharmaceutical companies and their suppliers to make informed decisions based on risk, cost, and CO2 emissions. By leveraging historical data from its extensive container fleet and advanced forecasting analytics, SkyMind can prevent medication losses with higher predictability. Additionally, the Decarbonize tool within the software suite allows clients to predict, track, and report CO2 emissions, optimizing routes to reduce their carbon footprint.
Richard Ettl, Co-Founder and CEO of SkyCell, highlighted the significance of this investment: “As the pharma industry experiences rapid growth from new biologics, there is an urgent need to decarbonize the supply chain. Our reusable 1500X container reduces CO2 emissions by 50 percent per use, saving over 250,000 tonnes of CO2 annually for a typical customer without compromising quality. Digitalisation is transforming pharma supply chains, moving from manual worksheets to integrated workflows that leverage our vast data pool. This new investment will further optimise supply chains, creating truly sustainable logistics.”
Bosun Hau, Managing Director and Head of Private Equity at Tybourne Capital Management, expressed his enthusiasm for joining SkyCell’s board: “SkyCell’s cutting-edge hardware, software, and tracking platform position it as the technology partner of choice for the global pharmaceutical industry. Managing risk in global supply chains is critical, particularly for pharma companies. SkyCell’s innovative system is transforming a traditionally stagnant industry.”
